WVE (Wave Pharma) Future Price to Earnings
Wave Life Sciences is preparing to launch innovative RNA-based drugs to combat genetic pathologies. The business relies on a unique stereopurity platform, capturing the precision medicine niche. Simultaneously, the company is implementing eco-friendly molecule synthesis to comply with ESG standards. The company's forward P/E ratio demonstrates earnings growth potential, where the 0.00 mark serves as the current real-time valuation.
Summary analytical data breakdowns for Wave Pharma (WVE)
- current price and projected stock value:
- business market valuation indicators:
- balance sheet equity data:
- debt obligations and liquidity statistics:
Total Debt to Capital Wave Life Sciences|WVE - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Wave Life Sciences|WVE - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Wave Life Sciences Ltd|WVE - Long-Term Debt Volume|Company Short-Term Debts Wave Life Sciences|Quick Ratio wavelifesciences.com
- earnings and market ratios statistics:
WVE - Net Financial Result|Projected Future Earnings Wave Life Sciences|WVE - Market Cap to Earnings|Future Price to Earnings Wave Life Sciences Corp|WVE - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Wave Life Sciences Ltd|WVE - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Wave Life Sciences|WVE - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months wavelifesciences.com|WVE - Expected net earnings per share growth this year|Expected earnings per share growth for next year Wave Life Sciences
- revenue and sales proceeds data:
Fundamental valuation:WVE Wave Life Sciences Ltd.
Investors must determine an asset's fair value through the lens of future earnings. This ratio compares the current quote with projected net income, revealing market imbalances between price and actual potential. By analyzing changes in the company's forward P/E level, one can identify phases of irrational exuberance or undervaluation. For Wave Life Sciences (WVE), this balance is maintained by retaining rare RNA therapy specialists. A stable workforce minimizes the risks associated with the realization of forecasts.
Main competitors
Projected Price to Earnings TEM (Tempus Labs)|QGEN (Qiagen NV) - Future Price to Earnings Multiple|Future Price to Earnings Ionis Pharma IONS|Repligen Inc. - Future Price to Earnings|Avidity Biosciences - Forward P/E Multiple|Market Cap to Projected Earnings crisprtx.com CRSP|WGS: Forward P/E Multiple|Price to Expected Earnings Ratio RARE (Ultragenyx Pharmaceutical Inc.)|BEAM (Beam Therapeutics Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio Sarepta Corp SRPT|Projected Price to Earnings TWST (Twist Bioscience)|TXG (10xgenomics.com) - Future Price to Earnings Multiple|Future Price to Earnings Intellia Therapeutics, Inc. NTLA|Market Cap to Projected Earnings Stoke Therapeutics Inc (STOK)|BioLife Corp - Forward P/E Multiple|Maze Therapeutics Corp (MAZE) - Projected Price to Earnings|SION: Forward P/E Multiple|PRME - Market Cap to Projected Earnings|TSHA (Taysha Gene Therapies, Inc.) - Forward P/E Multiple|Projected Price to Earnings Ratio uniQure NV QURE|Future Price to Earnings MeiraGTx PLC (MGTX)|REGENXBIO Corp - Price to Future Earnings Ratio|Forward P/E Multiple SLDB (Solid Biosciences Inc.)|OCGN - Projected Price to Earnings|PacBio - Forward P/E Multiple|Projected Price to Earnings Ratio Benitec Biopharma Inc|Design Pharma (DSGN) - Future Price to Earnings|RCKT - Market Cap to Projected Earnings|Projected Price to Earnings FDMT|Projected Price to Earnings Lexeo (LXEO)|Projected Price to Earnings KRRO (Korro Bio, Inc.)|Future Price to Earnings EDIT (Editas Medicine Inc)|Forward P/E Multiple SLN (Silence Therapeutics Inc.)|ProQR (PRQR) - Projected Price to Earnings Ratio|Codexis Bio - Forward P/E Multiple|SGMO (sangamo.com) - Price to Future Earnings Ratio|nautilus.bio (NAUT) - Future Price to Earnings|Price to Future Earnings Ratio MGX|DTIL (Precision BioSciences, Inc.) - Forward P/E Multiple|Forward P/E Multiple Generation Bio Corp|Projected Price to Earnings BOLD (Boundless Bio, Inc.)|Projected Price to Earnings exicuretx.com XCUR|Forward P/E Multiple IMNN (Imunon)|Forward P/E Multiple Phio Pharmaceuticals Corp PHIO|MBIO: Projected Price to Earnings|RNAZ: Future Price to Earnings|BNGO: Forward P/E Multiple|Projected Price to Earnings Ratio adnas.com (APDN)|Projected Price to Earnings BLUE|IPA: Future Price to Earnings Multiple|Future Price to Earnings Omega (OMGA)|Future Price to Earnings OMIC (Singular Genomics Corp)|Forward P/E Multiple RGLS (Regulus Therapeutics)|Market Cap to Projected Earnings syros.com (SYRS)|Telesis Bio - Forward P/E Multiple|Price to Expected Earnings Ratio TCON|UBX: Forward P/E Multiple
